179
Views
27
CrossRef citations to date
0
Altmetric
Research Article

Exploring the potential of lecithin/chitosan nanoparticles in enhancement of antihypertensive efficacy of hydrochlorothiazide

, , , &
Pages 805-812 | Received 29 Dec 2011, Accepted 02 May 2012, Published online: 09 Jun 2012

References

  • Chadha R, Arora P, Bhandari S, Jain DVS. Effect of hydrophilic polymer on complexing efficiency of cyclodextrins towards efavirenz-characterization and thermodynamic parameters. J Incl Phenom Macrocycl Chem 2012; 72: 275–87
  • Chakraborty S, Shukla D, Mishra B, Singh S. Lipid – An emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm 2009; 73: 1–15
  • Chandy T, Sharma CP. Chitosan—As a biomaterial. Artif Cells Blood Substitut Immobil Biotech 1990; 18: 1–24
  • Ellenhorn MJ, Barceloux DG. Medical toxicology-diagnosis and treatment of human poisoning. Elsevier Science Publishing Co., Inc, New York 1988
  • Hollabaugh CB, Burt LH, Walsh AP. Carboxymethyl cellulose…Uses and applications. Ind Eng Chem 1945; 37: 943–7
  • Kearney PM, Whelton M, Reynolds K. Global burden of hypertension: Analysis of worldwide data. Lancet 2005; 365: 217–23
  • Kh R, Khullarb M, Kashyapb M, Pandhi P, Uppala R. Effect of oral magnesium supplementation on blood pressure, platelet aggregation and calcium handling in deoxycorticosterone acetate induced hypertension in rats. J Hypertens 2000; 18: 919–26
  • Komatsu H, Kitajima A, Okada S. Pharmaceutical characterization of commercially available intravenous fat emulsions: Estimation of average particle size, size distribution and surface potential using photon correlation spectroscopy. Chem Pharm Bull 1995; 43: 1412–15
  • Magenheim B. A new in vitro technique for the evaluation of drug release profile from colloidal carriers ultrafiltration technique at low pressure. Int J Pharm 1993; 94: 115–23
  • Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001; 47: 3–19
  • Müller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – A review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161–77
  • Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Del Rev 2003; 55: 329–47
  • Pires MAS, Santos RAS, Sinisterra RD. Pharmaceutical composition of Hydrochlorothiazide:β-Cyclodextrin: Preparation by three different methods, physico-chemical characterization and in vivo diuretic activity evaluation. Molecules 2011; 16: 4482–99
  • Redhead HM, Davis SS, Illum L. Drug delivery in poly (lactide-coglycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: In vitro characterisation and in vivo evaluation. J Control Release 2001; 70: 353–63
  • Santos-Magalhães NS, Mosqueira VCF. Nanotechnology applied to the treatment of malaria. Adv Drug Delivery Rev 2010; 62(4–5)560–75
  • Shabouri MHE. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int J Pharm 2002; 249: 101–8
  • Shu XZ, Zhu KJ. Controlled drug release properties of ionically cross-linked chitosan beads: The influence of anion structure. Int J Pharm 2002; 233: 217–25
  • Sonvico F, Cagnania A, Rossi A, Motta S, Di Bari MT, Cavatortab F, Alonso MJ, Deriub A, Colomboa P. Formation of self-organized nanoparticles by lecithin/chitosan ionic interaction. Int J Pharm 2006; 324: 67–73
  • Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001; 70: 1–20
  • inc. TSRL, 2011. BCS (Biopharmaceutics Classification System). Available at: http://69.20.123.154/services/bcs/results.cfm. Accessed 15 December 2011
  • Vervaet C, Baert L, Remon JP. Enhancement of in vitro drug release by using polyethylene glycol 400 and PEG-40 hydrogenated castor oil in pellets made by extrusion/spheronisation. Int J Pharm 1994; 108: 207–12
  • Vervaet C, Remon JP. Bioavailability of hydrochlorothiazide from pellets, made by extrusion/spheronisation, containing polyethylene glycol 400 as a dissolution enhancer. Pharm Res 1997; 14: 1644–6

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.